Accelerated DNA methylation age plays a role in the impact of cardiovascular risk factors on the human heart
Abstract Background DNA methylation (DNAm) age acceleration (AgeAccel) and cardiac age by 12-lead advanced electrocardiography (A-ECG) are promising biomarkers of biological and cardiac aging, respectively. We aimed to explore the relationships between DNAm age and A-ECG heart age and to understand...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-10-01
|
| Series: | Clinical Epigenetics |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13148-023-01576-9 |
| _version_ | 1797558907599585280 |
|---|---|
| author | Constantin-Cristian Topriceanu Eesha Dev Mahmood Ahmad Rebecca Hughes Hunain Shiwani Matthew Webber Kenan Direk Andrew Wong Martin Ugander James C. Moon Alun D. Hughes Jane Maddock Todd T. Schlegel Gabriella Captur |
| author_facet | Constantin-Cristian Topriceanu Eesha Dev Mahmood Ahmad Rebecca Hughes Hunain Shiwani Matthew Webber Kenan Direk Andrew Wong Martin Ugander James C. Moon Alun D. Hughes Jane Maddock Todd T. Schlegel Gabriella Captur |
| author_sort | Constantin-Cristian Topriceanu |
| collection | DOAJ |
| description | Abstract Background DNA methylation (DNAm) age acceleration (AgeAccel) and cardiac age by 12-lead advanced electrocardiography (A-ECG) are promising biomarkers of biological and cardiac aging, respectively. We aimed to explore the relationships between DNAm age and A-ECG heart age and to understand the extent to which DNAm AgeAccel relates to cardiovascular (CV) risk factors in a British birth cohort from 1946. Results We studied four DNAm ages (AgeHannum, AgeHorvath, PhenoAge, and GrimAge) and their corresponding AgeAccel. Outcomes were the results from two publicly available ECG-based cardiac age scores: the Bayesian A-ECG-based heart age score of Lindow et al. 2022 and the deep neural network (DNN) ECG-based heart age score of Ribeiro et al. 2020. DNAm AgeAccel was also studied relative to results from two logistic regression-based A-ECG disease scores, one for left ventricular (LV) systolic dysfunction (LVSD), and one for LV electrical remodeling (LVER). Generalized linear models were used to explore the extent to which any associations between biological cardiometabolic risk factors (body mass index, hypertension, diabetes, high cholesterol, previous cardiovascular disease [CVD], and any CV risk factor) and the ECG-based outcomes are mediated by DNAm AgeAccel. We derived the total effects, average causal mediation effects (ACMEs), average direct effects (ADEs), and the proportion mediated [PM] with their 95% confidence intervals [CIs]. 498 participants (all 60–64 years) were included, with the youngest ECG heart age being 27 and the oldest 90. When exploring the associations between cardiometabolic risk factors and Bayesian A-ECG cardiac age, AgeAccelPheno appears to be a partial mediator, as ACME was 0.23 years [0.01, 0.52] p = 0.028 (i.e., PM≈18%) for diabetes, 0.34 [0.03, 0.74] p = 0.024 (i.e., PM≈15%) for high cholesterol, and 0.34 [0.03, 0.74] p = 0.024 (PM≈15%) for any CV risk factor. Similarly, AgeAccelGrim mediates ≈30% of the relationship between diabetes or high cholesterol and the DNN ECG-based heart age. When exploring the link between cardiometabolic risk factors and the A-ECG-based LVSD and LVER scores, it appears that AgeAccelPheno or AgeAccelGrim mediate 10–40% of these associations. Conclusion By the age of 60, participants with accelerated DNA methylation appear to have older, weaker, and more electrically impaired hearts. We show that the harmful effects of CV risk factors on cardiac age and health, appear to be partially mediated by DNAm AgeAccelPheno and AgeAccelGrim. This highlights the need to further investigate the potential cardioprotective effects of selective DNA methyltransferases modulators. |
| first_indexed | 2024-03-10T17:38:02Z |
| format | Article |
| id | doaj.art-e91430dc36f344b3b9b0d182e9b29e69 |
| institution | Directory Open Access Journal |
| issn | 1868-7083 |
| language | English |
| last_indexed | 2024-03-10T17:38:02Z |
| publishDate | 2023-10-01 |
| publisher | BMC |
| record_format | Article |
| series | Clinical Epigenetics |
| spelling | doaj.art-e91430dc36f344b3b9b0d182e9b29e692023-11-20T09:48:11ZengBMCClinical Epigenetics1868-70832023-10-0115111410.1186/s13148-023-01576-9Accelerated DNA methylation age plays a role in the impact of cardiovascular risk factors on the human heartConstantin-Cristian Topriceanu0Eesha Dev1Mahmood Ahmad2Rebecca Hughes3Hunain Shiwani4Matthew Webber5Kenan Direk6Andrew Wong7Martin Ugander8James C. Moon9Alun D. Hughes10Jane Maddock11Todd T. Schlegel12Gabriella Captur13UCL MRC Unit for Lifelong Health and Ageing, University College LondonUCL Medical SchoolCentre for Inherited Heart Muscle Conditions, The Royal Free HospitalUCL Institute of Cardiovascular Science, University College LondonUCL Institute of Cardiovascular Science, University College LondonUCL MRC Unit for Lifelong Health and Ageing, University College LondonUCL MRC Unit for Lifelong Health and Ageing, University College LondonUCL MRC Unit for Lifelong Health and Ageing, University College LondonKolling Institute Royal North Shore Hospital, and Charles Perkins Centre, Faculty of Medicine and Health, University of SydneyUCL Institute of Cardiovascular Science, University College LondonUCL MRC Unit for Lifelong Health and Ageing, University College LondonUCL MRC Unit for Lifelong Health and Ageing, University College LondonDepartment of Clinical Physiology, Karolinska University Hospital, and Karolinska InstitutetUCL MRC Unit for Lifelong Health and Ageing, University College LondonAbstract Background DNA methylation (DNAm) age acceleration (AgeAccel) and cardiac age by 12-lead advanced electrocardiography (A-ECG) are promising biomarkers of biological and cardiac aging, respectively. We aimed to explore the relationships between DNAm age and A-ECG heart age and to understand the extent to which DNAm AgeAccel relates to cardiovascular (CV) risk factors in a British birth cohort from 1946. Results We studied four DNAm ages (AgeHannum, AgeHorvath, PhenoAge, and GrimAge) and their corresponding AgeAccel. Outcomes were the results from two publicly available ECG-based cardiac age scores: the Bayesian A-ECG-based heart age score of Lindow et al. 2022 and the deep neural network (DNN) ECG-based heart age score of Ribeiro et al. 2020. DNAm AgeAccel was also studied relative to results from two logistic regression-based A-ECG disease scores, one for left ventricular (LV) systolic dysfunction (LVSD), and one for LV electrical remodeling (LVER). Generalized linear models were used to explore the extent to which any associations between biological cardiometabolic risk factors (body mass index, hypertension, diabetes, high cholesterol, previous cardiovascular disease [CVD], and any CV risk factor) and the ECG-based outcomes are mediated by DNAm AgeAccel. We derived the total effects, average causal mediation effects (ACMEs), average direct effects (ADEs), and the proportion mediated [PM] with their 95% confidence intervals [CIs]. 498 participants (all 60–64 years) were included, with the youngest ECG heart age being 27 and the oldest 90. When exploring the associations between cardiometabolic risk factors and Bayesian A-ECG cardiac age, AgeAccelPheno appears to be a partial mediator, as ACME was 0.23 years [0.01, 0.52] p = 0.028 (i.e., PM≈18%) for diabetes, 0.34 [0.03, 0.74] p = 0.024 (i.e., PM≈15%) for high cholesterol, and 0.34 [0.03, 0.74] p = 0.024 (PM≈15%) for any CV risk factor. Similarly, AgeAccelGrim mediates ≈30% of the relationship between diabetes or high cholesterol and the DNN ECG-based heart age. When exploring the link between cardiometabolic risk factors and the A-ECG-based LVSD and LVER scores, it appears that AgeAccelPheno or AgeAccelGrim mediate 10–40% of these associations. Conclusion By the age of 60, participants with accelerated DNA methylation appear to have older, weaker, and more electrically impaired hearts. We show that the harmful effects of CV risk factors on cardiac age and health, appear to be partially mediated by DNAm AgeAccelPheno and AgeAccelGrim. This highlights the need to further investigate the potential cardioprotective effects of selective DNA methyltransferases modulators.https://doi.org/10.1186/s13148-023-01576-9Advanced electrocardiographyAgingDNA methylation age |
| spellingShingle | Constantin-Cristian Topriceanu Eesha Dev Mahmood Ahmad Rebecca Hughes Hunain Shiwani Matthew Webber Kenan Direk Andrew Wong Martin Ugander James C. Moon Alun D. Hughes Jane Maddock Todd T. Schlegel Gabriella Captur Accelerated DNA methylation age plays a role in the impact of cardiovascular risk factors on the human heart Clinical Epigenetics Advanced electrocardiography Aging DNA methylation age |
| title | Accelerated DNA methylation age plays a role in the impact of cardiovascular risk factors on the human heart |
| title_full | Accelerated DNA methylation age plays a role in the impact of cardiovascular risk factors on the human heart |
| title_fullStr | Accelerated DNA methylation age plays a role in the impact of cardiovascular risk factors on the human heart |
| title_full_unstemmed | Accelerated DNA methylation age plays a role in the impact of cardiovascular risk factors on the human heart |
| title_short | Accelerated DNA methylation age plays a role in the impact of cardiovascular risk factors on the human heart |
| title_sort | accelerated dna methylation age plays a role in the impact of cardiovascular risk factors on the human heart |
| topic | Advanced electrocardiography Aging DNA methylation age |
| url | https://doi.org/10.1186/s13148-023-01576-9 |
| work_keys_str_mv | AT constantincristiantopriceanu accelerateddnamethylationageplaysaroleintheimpactofcardiovascularriskfactorsonthehumanheart AT eeshadev accelerateddnamethylationageplaysaroleintheimpactofcardiovascularriskfactorsonthehumanheart AT mahmoodahmad accelerateddnamethylationageplaysaroleintheimpactofcardiovascularriskfactorsonthehumanheart AT rebeccahughes accelerateddnamethylationageplaysaroleintheimpactofcardiovascularriskfactorsonthehumanheart AT hunainshiwani accelerateddnamethylationageplaysaroleintheimpactofcardiovascularriskfactorsonthehumanheart AT matthewwebber accelerateddnamethylationageplaysaroleintheimpactofcardiovascularriskfactorsonthehumanheart AT kenandirek accelerateddnamethylationageplaysaroleintheimpactofcardiovascularriskfactorsonthehumanheart AT andrewwong accelerateddnamethylationageplaysaroleintheimpactofcardiovascularriskfactorsonthehumanheart AT martinugander accelerateddnamethylationageplaysaroleintheimpactofcardiovascularriskfactorsonthehumanheart AT jamescmoon accelerateddnamethylationageplaysaroleintheimpactofcardiovascularriskfactorsonthehumanheart AT alundhughes accelerateddnamethylationageplaysaroleintheimpactofcardiovascularriskfactorsonthehumanheart AT janemaddock accelerateddnamethylationageplaysaroleintheimpactofcardiovascularriskfactorsonthehumanheart AT toddtschlegel accelerateddnamethylationageplaysaroleintheimpactofcardiovascularriskfactorsonthehumanheart AT gabriellacaptur accelerateddnamethylationageplaysaroleintheimpactofcardiovascularriskfactorsonthehumanheart |